Literature DB >> 8850464

Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies.

H B Ris1, H J Altermatt, B Nachbur, C M Stewart, Q Wang, C K Lim, R Bonnett, U Althaus.   

Abstract

BACKGROUND AND
OBJECTIVE: Since there is no satisfactory treatment modality for diffuse malignant mesothelioma of the chest, we assessed surgical tumor resection followed by intraoperative photodynamic therapy with mTHPC in a phase I study. STUDY DESIGN/
MATERIALS AND METHODS: Since 1990, eight patients have undergone intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin (mTHPC-PDT) following thoracotomy and surgical tumor resection.
RESULTS: mTHPC-PDT-mediated tumor necrosis was characterized by tumor infarction due to tumor vessel necrosis and thrombosis, and its extent depended on drug-light conditions; 650 nm light delivered at 0.1 W/cm2 for 10 J/cm2 48 h after iv administration of 0.3 mg mTHPC/kg resulted in a 10-mm-deep complete tumor necrosis. Skin photosensitivity was related to the drug dose applied and occurred up to 17 days after iv administration of 0.3 mg mTHPC/kg, mTHPC-PDT of brachial plexus infiltrated by mesothelioma resulted in pain relief without deterioration of nerve function.
CONCLUSION: Tumor resection and intraoperative mTHPC-PDT of the chest cavity is feasible under clinical conditions and offers local tumor control of sites involved. However, distant tumor spread was not prevented by this combined treatment modality and optimization of mTHPC-PDT is warranted for further intraoperative application.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8850464     DOI: 10.1002/(SICI)1096-9101(1996)18:1<39::AID-LSM5>3.0.CO;2-S

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  6 in total

1.  Photodynamic therapy of disseminated non-small cell lung carcinoma in a murine model.

Authors:  Craig E Grossman; Stephen Pickup; Amy Durham; E Paul Wileyto; Mary E Putt; Theresa M Busch
Journal:  Lasers Surg Med       Date:  2011-09       Impact factor: 4.025

2.  Peripheral neural cell sensitivity to mTHPC-mediated photodynamic therapy in a 3D in vitro model.

Authors:  K E Wright; E Liniker; M Loizidou; C Moore; A J Macrobert; J B Phillips
Journal:  Br J Cancer       Date:  2009-07-28       Impact factor: 7.640

3.  Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies.

Authors:  P Baas; L Murrer; F A Zoetmulder; F A Stewart; H B Ris; N van Zandwijk; J L Peterse; E J Rutgers
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 4.  Photodynamic therapy for mesothelioma.

Authors:  S M Hahn; R P Smith; J Friedberg
Journal:  Curr Treat Options Oncol       Date:  2001-10

5.  Uptake and localisation of mTHPC (Foscan) and its 14C-labelled form in normal and tumour tissues of the hamster squamous cell carcinoma model: a comparative study.

Authors:  S Andrejevic Blant; T M Glanzmann; J-P Ballini; G Wagnières; H van den Bergh; P Monnier
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

6.  Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan localisation in cultured tumour cells.

Authors:  M-H Teiten; L Bezdetnaya; P Morlière; R Santus; F Guillemin
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.